NCT03242928View on ClinicalTrials.gov

Study to Investigate Whether AFQ056 Reduces Cocaine Use in Patients Diagnosed With Cocaine Use Disorder (CUD)

PHASE2CompletedINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

December 4, 2017

Primary Completion Date

December 16, 2019

Study Completion Date

December 16, 2019

Conditions
Cocaine-related Disorder
Interventions
DRUG

AFQ056

50 mg and 100 mg tablets taken orally

DRUG

Placebo

Matching placebo tablets taken orally BID

Trial Locations (8)

1058

Novartis Investigative Site, Buenos Aires

4025

Novartis Investigative Site, Basel

4634

Novartis Investigative Site, Buenos Aires

8001

Novartis Investigative Site, Zurich

C1405B0A

Novartis Investigative Site, Buenos Aires

03550

Novartis Investigative Site, Sant Joan d'Alacant

08003

Novartis Investigative Site, Barcelona

08036

Novartis Investigative Site, Barcelona

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY